Follow
Jaime Espín Balbino
Jaime Espín Balbino
Escuela Andaluza de Salud Pública
Verified email at easp.es
Title
Cited by
Cited by
Year
Analysis of differences and commonalities in pricing and reimbursement systems in Europe
J Espin, J Rovira
Brussels: DG Enterprise and Industry of the European Commission 100, 2007
1352007
Cumulative risk of second primary contralateral breast cancer in BRCA1/BRCA2 mutation carriers with a first breast cancer: a systematic review and meta-analysis
E Molina-Montes, B Pérez-Nevot, M Pollán, E Sánchez-Cantalejo, J Espín, ...
The Breast 23 (6), 721-742, 2014
1042014
Risk of second cancers cancer after a first primary breast cancer: a systematic review and meta-analysis
E Molina-Montes, M Requena, E Sánchez-Cantalejo, MF Fernández, ...
Gynecologic oncology 136 (1), 158-171, 2015
1022015
A general framework for classifying costing methods for economic evaluation of health care
Z Špacírová, D Epstein, L García-Mochón, J Rovira, A Olry de Labry Lima, ...
The European Journal of Health Economics 21 (4), 529-542, 2020
722020
Experiences and impact of European risk-sharing schemes focusing on oncology medicines
J Espín, J Rovira, L García
Brussels: Commissioned by the European Commission, Directorate-General …, 2011
652011
How can voluntary cross-border collaboration in public procurement improve access to health technologies in Europe
J Espín, J Rovira, A Calleja, N Azzopardi-Muscat, E Richardson, W Palm, ...
Health systems and policy analysis, policy brief 21, 2016
542016
The impact of biosimilars’ entry in the EU market
J Rovira, J Espín, L García, A Olry de Labry
Andalusian Sch Pub Health 30, 1-83, 2011
532011
Pandemic influenza control in Europe and the constraints resulting from incoherent public health laws
R Martin, A Conseil, A Longstaff, J Kodo, J Siegert, AM Duguet, ...
BMC Public Health 10, 1-10, 2010
522010
Esquemas innovadores de mejora del acceso al mercado de nuevas tecnologías: los acuerdos de riesgo compartido
J Espín, J Oliva, JM Rodríguez-Barrios
Gaceta Sanitaria 24, 491-497, 2010
51*2010
Pharmaceutical pricing and reimbursement information (PPRI)–New PPRI analysis including Spain
S Vogler, J Espin, C Habl
Pharmaceuticals Policy and Law 11 (3), 213-234, 2009
512009
Short-and long-term effects of value-based pricing vs. external price referencing
P Kanavos, E Nicod, J Espin, S Van Den Aardweg
Eminet, LSE, 2010
422010
Personalised medicine as a challenge for public pricing and reimbursement authorities–A survey among 27 European countries on the example of trastuzumab
C Leopold, S Vogler, C Habl, AK Mantel-Teeuwisse, J Espin
Health Policy 113 (3), 313-322, 2013
392013
Working paper 1: External price referencing–review series on pharmaceutical pricing policies and interventions
J Espin, J Rovira, AO de Labry
Geneva: World Health Organization and Health Action International, 2011
392011
Projecting pharmaceutical expenditure in EU5 to 2021: adjusting for the impact of discounts and rebates
J Espin, M Schlander, B Godman, P Anderson, J Mestre-Ferrandiz, ...
Applied health economics and health policy 16 (6), 803-817, 2018
372018
Multiple criteria decision analysis for HTA across four EU member states: piloting the advance value framework
A Angelis, M Linch, G Montibeller, T Molina-Lopez, A Zawada, K Orzel, ...
Social Science & Medicine 246, 112595, 2020
342020
Medicine Prices in Latin American Countries
JE Balbino, JR Forns, CV González
Medicine Price Surveys, Analyses and Comparisons, 61-83, 2019
33*2019
Implementing outcomes-based managed entry agreements for rare disease treatments: nusinersen and tisagenlecleucel
KM Facey, J Espin, E Kent, A Link, E Nicod, A O’Leary, E Xoxi, ...
Pharmacoeconomics 39, 1021-1044, 2021
302021
Evaluation of new medicines in Spain and comparison with other European countries
D Epstein, J Espín
Gaceta sanitaria 34, 133-140, 2020
282020
HTA and decision-making processes in Central, Eastern and South Eastern Europe: Results from a survey
L García-Mochón, JE Balbino, AO de Labry Lima, AC Martinez, EM Ruiz, ...
Health Policy 123 (2), 182-190, 2019
282019
The use of nonrandomized evidence to estimate treatment effects in health technology assessment
S Kent, M Salcher-Konrad, S Boccia, JC Bouvy, C Waure, J Espin, ...
Journal of comparative effectiveness research 10 (14), 1035-1043, 2021
262021
The system can't perform the operation now. Try again later.
Articles 1–20